Canada's Rubicon Organics Q4 revenue beats estimates on higher production

Rubicon Organics

24/03/2026 11:38

Overview

Canada premium cannabis producer's Q4 net revenue rose 16% yr/yr, beating analyst expectations

Q4 adjusted EBITDA reached C$1.2 mln, up from prior year

Company growth driven by expanded capacity and Cascadia facility integration

Outlook

Rubicon Organics forecasts growth in net revenue and Adjusted EBITDA for 2026

Company expects gross margin and Adjusted EBITDA to be under pressure in H1 2026

Rubicon Organics expects margin and cash flow improvements in H2 2026 as Cascadia production ramps up

Result Drivers

EXPANDED CAPACITY - Q4 revenue growth attributed to increased production capacity from Cascadia facility integration

SUPPLY CONSTRAINTS - Demand for flower products exceeded available supply, supporting revenue growth

MARGIN INITIATIVES - Co pursuing facility optimization and genetic selection to improve gross margin

Company press release: ID:nGNX8XmXFz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
C$16.50 mln
C$15.87 mln (3 Analysts)
Q4 Adjusted EBITDA
C$1.20 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Rubicon Organics Inc is C$1.15, about 134.7% above its March 23 closing price of C$0.49

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)